We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Medicyte GmbH and Reinnervate Ltd to Collaborate
News

Medicyte GmbH and Reinnervate Ltd to Collaborate

Medicyte GmbH and Reinnervate Ltd to Collaborate
News

Medicyte GmbH and Reinnervate Ltd to Collaborate

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Medicyte GmbH and Reinnervate Ltd to Collaborate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medicyte and Reinnervate said they will work together to combine their upcyte® and Alvetex®Scaffold technologies to bring next generation cell bases assays to the biopharma and academic research markets.

Early data, already presented at academic meetings, indicates that Medicyte’s upcyte® hepatocytes combine the benefits of quantity (generation of up to 2000 vials per donor) with the quality of primary hepatocytes. Furthermore, upcyte® hepatocytes, grown with a more native 3D morphology in Reinnervate’s alvetex scaffold, seem to outperform their 2D counterparts.

‘We are delighted that Medicyte have chosen to put Alvetex®Scaffold at the heart of their new product development plans’ commented Prof Stefan Przyborski, CSO of Reinnervate Ltd. ‘The ability of 3D cells to better predict in vivo responses to therapeutic and environmental challenges makes alvetex scaffold technology an important new tool for scientists’ he added.

‘We are excited about working with Reinnervate to explore the growing area of 3D cell culture. The combination of both technologies will undoubtedly lead to a more predictive culture model without the limitation of cell supply’ commented Dr. Joris Braspenning, Managing Director of Medicyte GmbH. The two companies did not disclose financial terms relating to the collaboration.

Advertisement